ArticleMagnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine2026
Preparation and MR Imaging Study of a Recombinant Surface Antibody Superparamagnetic Iron Oxide Nanoparticle-EPC1 Molecular Probe for Hepatic Alveolar Echinococcosis.
Article in Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo establish a new hepatic alveolar echinococcosis (HAE) model, construct an EPC1 antibody-conjugated superparamagnetic iron oxide nanoparticle (SPION) molecular probe and evaluate the probe's efficacy in the targeted MRI of HAE.
methodsThirty C57 female mice (9-10 weeks; 17-22g) were used to establish an HAE model via hepatic portal vein infection. Twenty successfully HAE-modeled mice were randomly divided into a control group, which was given a simple SPION tracer, and an experimental group, which was given a complex SPION-EPC1 tracer. In addition, a blocking group (n = 5), in which mice received an excess dose of free EPC1 antibody prior to injection of the SPION-EPC1 tracer, was included to assess EPC1-dependent targeting, and a gadolinium-diethylene triamine pentaacetic acid (Gd-DTPA) group (n = 5), which received 0.1 mmol/kg of Gd-DTPA, was included to provide a reference clinical contrast agent. MRI was performed using an animal MRI scanner, and T1- and T2-weighted imaging sequences were utilized to assess lesion characteristics before and after tracer injection at 1 and 4h time points. Subsequently, T2 signal intensity, the lesion SNR, and the lesion-to-liver contrast-to-noise ratio were measured by 2 blinded physicians (>5 years experience) using ImageJ software. Comparisons were made between plain and post-injection scans at 1 and 4h. Independent sample t-tests and non-parametric tests were applied to compare signal intensities and SNR values.
resultsThe SPION-EPC1 probe significantly decreased T2 signal intensity and lesion SNR in the experimental group at both 1 (T2 intensity: -24.3%; SNR: -35.2%) and 4h (T2 intensity: -23.5%; SNR: -43.1%) compared with plain scans. By contrast, the control group showed only transient decreases, with no significant differences at 4h. In the EPC1-blocking group, the T2-signal decrease at 4h was markedly attenuated compared with that of the SPION-EPC1 group and comparable to that of the SPION group, supporting EPC1-dependent targeting.
conclusionThe SPION-EPC1 molecular probe demonstrated improved sensitivity and long-lasting effects in the MRI detection of HAE lesions, offering a promising tool for early diagnosis and the potential advancement of clinical practice in HAE imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.